4 analysts have expressed a variety of opinions on Recursion Pharmaceuticals (NASDAQ:RXRX) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Learn how to speak with a more American accent! Marina shares some tips. Taliban reacts to Trump's comments on Bagram base in Afghanistan A Massive New Study Says This Is What Happens to People Who ...

On September 1st, the author and statistician Nate Silver wrote a post on X diagnosing a new condition: “Blueskyism,” so named for the decentralized social network that has emerged as a competitor to ...